Furthermore, in the PD-L1 expression level subgroup, for patients with tumor PD-L1 expression ≥50%, the HR value are 0.24 (0.10-0.61) for Nivolumab, 0.60 (0.35-1.01) for Durvalumab, and 0.42 (0.28-0.65) for Pembrolizumab. This evidence concerns the gene CD274 and neoplasm.